Browse CD3E

Summary
SymbolCD3E
NameCD3e molecule, epsilon (CD3-TCR complex)
Aliases CD3e antigen, epsilon polypeptide (TiT3 complex); IMD18; T3E; TCRE; CD3-epsilon; T-cell antigen receptor com ......
Chromosomal Location11q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Single-pass type I membrane protein
Domain PF02189 Immunoreceptor tyrosine-based activation motif
Function

Part of the TCR-CD3 complex present on T-lymphocyte cell surface that plays an essential role in adaptive immune response. When antigen presenting cells (APCs) activate T-cell receptor (TCR), TCR-mediated signals are transmitted across the cell membrane by the CD3 chains CD3D, CD3E, CD3G and CD3Z. All CD3 chains contain immunoreceptor tyrosine-based activation motifs (ITAMs) in their cytoplasmic domain. Upon TCR engagement, these motifs become phosphorylated by Src family protein tyrosine kinases LCK and FYN, resulting in the activation of downstream signaling pathways (PubMed:2470098). In addition of this role of signal transduction in T-cell activation, CD3E plays an essential role in correct T-cell developement. Initiates the TCR-CD3 complex assembly by forming the two heterodimers CD3D/CD3E and CD3G/CD3E. Participates also in internalization and cell surface down-regulation of TCR-CD3 complexes via endocytosis sequences present in CD3E cytosolic region (PubMed:10384095, PubMed:26507128).

> Gene Ontology
 
Biological Process GO:0001819 positive regulation of cytokine production
GO:0002249 lymphocyte anergy
GO:0002429 immune response-activating cell surface receptor signaling pathway
GO:0002507 tolerance induction
GO:0002517 T cell tolerance induction
GO:0002521 leukocyte differentiation
GO:0002643 regulation of tolerance induction
GO:0002645 positive regulation of tolerance induction
GO:0002664 regulation of T cell tolerance induction
GO:0002666 positive regulation of T cell tolerance induction
GO:0002667 regulation of T cell anergy
GO:0002669 positive regulation of T cell anergy
GO:0002694 regulation of leukocyte activation
GO:0002696 positive regulation of leukocyte activation
GO:0002757 immune response-activating signal transduction
GO:0002764 immune response-regulating signaling pathway
GO:0002768 immune response-regulating cell surface receptor signaling pathway
GO:0002870 T cell anergy
GO:0002911 regulation of lymphocyte anergy
GO:0002913 positive regulation of lymphocyte anergy
GO:0007159 leukocyte cell-cell adhesion
GO:0007172 signal complex assembly
GO:0007224 smoothened signaling pathway
GO:0007584 response to nutrient
GO:0008589 regulation of smoothened signaling pathway
GO:0009991 response to extracellular stimulus
GO:0018108 peptidyl-tyrosine phosphorylation
GO:0018212 peptidyl-tyrosine modification
GO:0019722 calcium-mediated signaling
GO:0019932 second-messenger-mediated signaling
GO:0022407 regulation of cell-cell adhesion
GO:0022409 positive regulation of cell-cell adhesion
GO:0030098 lymphocyte differentiation
GO:0030217 T cell differentiation
GO:0031294 lymphocyte costimulation
GO:0031295 T cell costimulation
GO:0031667 response to nutrient levels
GO:0032609 interferon-gamma production
GO:0032623 interleukin-2 production
GO:0032633 interleukin-4 production
GO:0032649 regulation of interferon-gamma production
GO:0032663 regulation of interleukin-2 production
GO:0032673 regulation of interleukin-4 production
GO:0032729 positive regulation of interferon-gamma production
GO:0032743 positive regulation of interleukin-2 production
GO:0032753 positive regulation of interleukin-4 production
GO:0032943 mononuclear cell proliferation
GO:0032944 regulation of mononuclear cell proliferation
GO:0032946 positive regulation of mononuclear cell proliferation
GO:0033077 T cell differentiation in thymus
GO:0042035 regulation of cytokine biosynthetic process
GO:0042089 cytokine biosynthetic process
GO:0042094 interleukin-2 biosynthetic process
GO:0042098 T cell proliferation
GO:0042102 positive regulation of T cell proliferation
GO:0042107 cytokine metabolic process
GO:0042108 positive regulation of cytokine biosynthetic process
GO:0042110 T cell activation
GO:0042129 regulation of T cell proliferation
GO:0043383 negative T cell selection
GO:0045058 T cell selection
GO:0045060 negative thymic T cell selection
GO:0045061 thymic T cell selection
GO:0045076 regulation of interleukin-2 biosynthetic process
GO:0045086 positive regulation of interleukin-2 biosynthetic process
GO:0045785 positive regulation of cell adhesion
GO:0045879 negative regulation of smoothened signaling pathway
GO:0046631 alpha-beta T cell activation
GO:0046633 alpha-beta T cell proliferation
GO:0046634 regulation of alpha-beta T cell activation
GO:0046635 positive regulation of alpha-beta T cell activation
GO:0046640 regulation of alpha-beta T cell proliferation
GO:0046641 positive regulation of alpha-beta T cell proliferation
GO:0046651 lymphocyte proliferation
GO:0050670 regulation of lymphocyte proliferation
GO:0050671 positive regulation of lymphocyte proliferation
GO:0050730 regulation of peptidyl-tyrosine phosphorylation
GO:0050731 positive regulation of peptidyl-tyrosine phosphorylation
GO:0050848 regulation of calcium-mediated signaling
GO:0050850 positive regulation of calcium-mediated signaling
GO:0050851 antigen receptor-mediated signaling pathway
GO:0050852 T cell receptor signaling pathway
GO:0050863 regulation of T cell activation
GO:0050865 regulation of cell activation
GO:0050867 positive regulation of cell activation
GO:0050870 positive regulation of T cell activation
GO:0051249 regulation of lymphocyte activation
GO:0051251 positive regulation of lymphocyte activation
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0070661 leukocyte proliferation
GO:0070663 regulation of leukocyte proliferation
GO:0070665 positive regulation of leukocyte proliferation
GO:0071593 lymphocyte aggregation
GO:0071594 thymocyte aggregation
GO:1903037 regulation of leukocyte cell-cell adhesion
GO:1903039 positive regulation of leukocyte cell-cell adhesion
Molecular Function GO:0005057 receptor signaling protein activity
GO:0017124 SH3 domain binding
GO:0030159 receptor signaling complex scaffold activity
GO:0032947 protein complex scaffold
GO:0042608 T cell receptor binding
GO:0046982 protein heterodimerization activity
Cellular Component GO:0001772 immunological synapse
GO:0009897 external side of plasma membrane
GO:0042101 T cell receptor complex
GO:0042105 alpha-beta T cell receptor complex
GO:0043235 receptor complex
GO:0098552 side of membrane
GO:0098802 plasma membrane receptor complex
> KEGG and Reactome Pathway
 
KEGG hsa04640 Hematopoietic cell lineage
hsa04660 T cell receptor signaling pathway
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-388841: Costimulation by the CD28 family
R-HSA-202424: Downstream TCR signaling
R-HSA-202433: Generation of second messenger molecules
R-HSA-168256: Immune System
R-HSA-198933: Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
R-HSA-389948: PD-1 signaling
R-HSA-202427: Phosphorylation of CD3 and TCR zeta chains
R-HSA-202403: TCR signaling
R-HSA-202430: Translocation of ZAP-70 to Immunological synapse
Summary
SymbolCD3E
NameCD3e molecule, epsilon (CD3-TCR complex)
Aliases CD3e antigen, epsilon polypeptide (TiT3 complex); IMD18; T3E; TCRE; CD3-epsilon; T-cell antigen receptor com ......
Chromosomal Location11q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CD3E and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between CD3E and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
27406985Prostate carcinomaPromote immunity (T cell function)We have developed a novel humanized bispecific antibody, MOR209/ES414, built on the ADAPTIR (modular protein technology) platform, to redirect T-cell cytotoxicity toward prostate cancer cells by specifically targeting T cells through CD3ε to prostate cancer cells expressing PSMA (prostate-specific membrane antigen).
Summary
SymbolCD3E
NameCD3e molecule, epsilon (CD3-TCR complex)
Aliases CD3e antigen, epsilon polypeptide (TiT3 complex); IMD18; T3E; TCRE; CD3-epsilon; T-cell antigen receptor com ......
Chromosomal Location11q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CD3E in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCD3E
NameCD3e molecule, epsilon (CD3-TCR complex)
Aliases CD3e antigen, epsilon polypeptide (TiT3 complex); IMD18; T3E; TCRE; CD3-epsilon; T-cell antigen receptor com ......
Chromosomal Location11q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CD3E in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.2580.697
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.4130.825
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.1440.921
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.6990.307
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.7610.573
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.6180.694
729033130MelanomaallAnti-PD-1 (nivolumab) 26231.2050.0768
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.6620.179
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.6810.623
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 482.610.0978
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 282.2220.374
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0530.818
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CD3E in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCD3E
NameCD3e molecule, epsilon (CD3-TCR complex)
Aliases CD3e antigen, epsilon polypeptide (TiT3 complex); IMD18; T3E; TCRE; CD3-epsilon; T-cell antigen receptor com ......
Chromosomal Location11q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CD3E. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCD3E
NameCD3e molecule, epsilon (CD3-TCR complex)
Aliases CD3e antigen, epsilon polypeptide (TiT3 complex); IMD18; T3E; TCRE; CD3-epsilon; T-cell antigen receptor com ......
Chromosomal Location11q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CD3E. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CD3E.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCD3E
NameCD3e molecule, epsilon (CD3-TCR complex)
Aliases CD3e antigen, epsilon polypeptide (TiT3 complex); IMD18; T3E; TCRE; CD3-epsilon; T-cell antigen receptor com ......
Chromosomal Location11q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CD3E. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCD3E
NameCD3e molecule, epsilon (CD3-TCR complex)
Aliases CD3e antigen, epsilon polypeptide (TiT3 complex); IMD18; T3E; TCRE; CD3-epsilon; T-cell antigen receptor com ......
Chromosomal Location11q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CD3E expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCD3E
NameCD3e molecule, epsilon (CD3-TCR complex)
Aliases CD3e antigen, epsilon polypeptide (TiT3 complex); IMD18; T3E; TCRE; CD3-epsilon; T-cell antigen receptor com ......
Chromosomal Location11q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CD3E and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCD3E
NameCD3e molecule, epsilon (CD3-TCR complex)
Aliases CD3e antigen, epsilon polypeptide (TiT3 complex); IMD18; T3E; TCRE; CD3-epsilon; T-cell antigen receptor com ......
Chromosomal Location11q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CD3E collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting CD3E.
ID Name Drug Type Targets #Targets
DB00075MuromonabBiotechC1QA, C1QB, C1QC, C1R, C1S, CD247, CD3D, CD3E, CD3G, FCGR1A, FCGR2 ......15
DB06607CatumaxomabBiotechCD3E, EPCAM, FCGR1A, FCGR2A, FCGR3A, FCGR3B6